Bazim V Ojeh1, Isaac O Abah2, Placid Ugoagwu3, Patricia A Agaba4, Oche O Agbaji5, Steven S Gyang6. 1. Bpharm, MSc, AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, P.M.B 2076 Jos, Nigeria. 2. BPharm, MSc, MPH, Pharmacy Department, Jos University Teaching Hospital, P.M.B 2076 Jos, Nigeria. 3. BSc, AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, P.M.B 2076 Jos, Nigeria. 4. BmBcH, FWACP, Department of Family Medicine, University of Jos, P.M.B 2084 Jos, Nigeria. 5. MBBS, FMCP, Department of Medicine, University of Jos, Jos University Teaching Hospital, P.M.B 2076 Jos, Nigeria. 6. Bpharm, MSc, PhD, Department of Pharmacology, University of Jos. P.M.B 2084 Jos, Nigeria.
Abstract
INTRODUCTION: The use of tenofovir disoproxil fumarate (TDF) in the treatment of HIV infection has been associated with renal dysfunction. In Nigeria, data on the incidence and risk factors of TDF nephrotoxicity is sparse. We determined the cumulative incidence of and risk factors for TDF-induced renal impairment in HIV-infected individuals accessing care at the antiretroviral therapy (ART) clinic of Jos University Teaching Hospital, Nigeria. METHODS: This retrospective cohort analysis included patients aged ≥16 years that initiated ART between January 2008 and December 2011. Renal impairment, defined as glomerular filtration rate GFR <60 mL/min/1.73 sqm using the Modification of Diet in Renal Disease (MDRD) equation was assessed at baseline and at 48 weeks on ART. Logistic regression was performed to determine factors associated with incident renal impairment. RESULTS: The mean age was 39±9 years, and 67.1% were female. The cumulative incidence of renal impairment among the TDF-exposed and TDF-unexposed groups was 4.6% and 2.3% respectively (p<0.001). TDF exposure was significantly associated with renal impairment [OR=2.0, 95%CI=(1.48-2.89), p<0.001] in bivariate analysis. In multivariate analysis, older age (aOR=1.06, 95%CI=(1.05-1.08), p<0.001), TDF exposure [aOR=1.85, 95%CI=(1.31-2.60), p<0.001] and co-morbidities [aOR=2.71, 95%CI=(1.72-4.25), p<0.001] were significantly associated with renal impairment. CONCLUSION: TDF exposure, aging and comorbidities were predictors of renal toxicity among HIV positive patients. Regular monitoring of renal function in such high-risk individuals is recommended.
INTRODUCTION: The use of tenofovir disoproxil fumarate (TDF) in the treatment of HIV infection has been associated with renal dysfunction. In Nigeria, data on the incidence and risk factors of TDF nephrotoxicity is sparse. We determined the cumulative incidence of and risk factors for TDF-induced renal impairment in HIV-infected individuals accessing care at the antiretroviral therapy (ART) clinic of Jos University Teaching Hospital, Nigeria. METHODS: This retrospective cohort analysis included patients aged ≥16 years that initiated ART between January 2008 and December 2011. Renal impairment, defined as glomerular filtration rate GFR <60 mL/min/1.73 sqm using the Modification of Diet in Renal Disease (MDRD) equation was assessed at baseline and at 48 weeks on ART. Logistic regression was performed to determine factors associated with incident renal impairment. RESULTS: The mean age was 39±9 years, and 67.1% were female. The cumulative incidence of renal impairment among the TDF-exposed and TDF-unexposed groups was 4.6% and 2.3% respectively (p<0.001). TDF exposure was significantly associated with renal impairment [OR=2.0, 95%CI=(1.48-2.89), p<0.001] in bivariate analysis. In multivariate analysis, older age (aOR=1.06, 95%CI=(1.05-1.08), p<0.001), TDF exposure [aOR=1.85, 95%CI=(1.31-2.60), p<0.001] and co-morbidities [aOR=2.71, 95%CI=(1.72-4.25), p<0.001] were significantly associated with renal impairment. CONCLUSION: TDF exposure, aging and comorbidities were predictors of renal toxicity among HIV positive patients. Regular monitoring of renal function in such high-risk individuals is recommended.
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Reneé De Waal; Karen Cohen; Matthew P Fox; Kathryn Stinson; Gary Maartens; Andrew Boulle; Ehimario U Igumbor; Mary-Ann Davies Journal: J Int AIDS Soc Date: 2017-04-10 Impact factor: 5.396
Authors: Tino Salome; Ivan Kasamba; Billy Nsubuga Mayanja; Patrick Kazooba; Jackson Were; Pontiano Kaleebu; Paula Munderi Journal: AIDS Res Ther Date: 2016-08-30 Impact factor: 2.250